Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2

(2016) Jason G. Kettle et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

(2015) S J Thomas et al.   BRITISH JOURNAL OF CANCER

Development of Selective Covalent Janus Kinase 3 Inhibitors

(2015) Li Tan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases

(2015) Daniella M. Schwartz et al.   Nature Reviews Rheumatology

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy

(2014) Fiona Tan et al.   CURRENT DRUG TARGETS

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

(2014) Christel J. Menet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacological targeting of the pseudokinase Her3

(2014) Ting Xie et al.   Nature Chemical Biology

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012

(2013) Brian W Dymock et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

(2013) Qibin Su et al.   JOURNAL OF MEDICINAL CHEMISTRY

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biology and significance of the JAK/STAT signalling pathways

(2012) Hiu Kiu et al.   GROWTH FACTORS

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies

(2012) Pasquale Sansone et al.   JOURNAL OF CLINICAL ONCOLOGY

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779

(2012) Benjamin J. Dugan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells

(2011) Zhenjie Yin et al.   ACTA HISTOCHEMICA

BCR-ABL1—Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment

(2011) Erik Vakil et al.   Clinical Lymphoma Myeloma & Leukemia

Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

(2010) Stephanos Ioannidis et al.   JOURNAL OF MEDICINAL CHEMISTRY

Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole

(2009) Tiansheng Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of Stat3 in suppressing anti-tumor immunity

(2008) Marcin Kortylewski et al.   CURRENT OPINION IN IMMUNOLOGY

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD